Abstract
Both Iodine-125 (125I) COMS and Ruthenium-106 (106Ru) eye plaques have the potential to achieve excellent tumor control in patients treated for uveal melanoma. We therefore evaluated our single institutional experience in the management of ocular melanoma treated with 125I and 106Ru plaque brachytherapy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology, Biology, Physics
Paper Title
Journal
Date
